Cambrian expands fibrosis pipeline
Cambrian BioPharma has unveiled its latest pipeline company, Isterian Biotech. The preclinical start-up is working towards the development of first-in-class small molecule inhibitors of transglutaminase 2 (TG2), one of the major crosslinking enzymes in the human body, which becomes more active during ageing, resulting in fibrotic diseases. Read More